AndroGel (Testosterone Topical) Gynecomastia Severity Grading Rubric

Why AndroGel Causes Gynecomastia

AndroGel raises serum testosterone by design. The problem is that roughly 0.3 to 0.5% of circulating testosterone converts enzymatically to 17-beta estradiol via the CYP19A1 aromatase enzyme, which sits in adipose tissue, liver, skin, and the testes. When that conversion outpaces the hypothalamic-pituitary axis's ability to suppress endogenous production, total estradiol rises, and the estrogen-to-androgen ratio tips toward a pro-estrogenic state. Breast glandular tissue, which is exquisitely sensitive to estradiol signaling, begins to proliferate.

The Aromatization Pathway in Detail

Testosterone serves as the direct precursor to estradiol. Aromatase hydroxylates the A-ring of the testosterone molecule, producing estrone first and then estradiol through a series of oxidation steps. Men with higher body-fat percentages carry more peripheral aromatase, so the same AndroGel dose produces more estradiol in a man with a body mass index of 32 than in a lean man with a BMI of 22. This partly explains why gynecomastia risk is not uniform across patients.

The FDA-approved prescribing information for AndroGel 1.62% lists gynecomastia among post-marketing adverse reactions and flags it as a possible outcome in the adverse-reactions section of the label. [1] A 2010 population-based cohort study in the British Journal of Clinical Pharmacology found that exogenous androgen use was independently associated with a threefold increase in gynecomastia risk compared with non-users (odds ratio 3.1, 95% CI 1.8 to 5.4). [2]

The Estrogen-Androgen Ratio: What the Numbers Mean

Serum estradiol alone does not tell the full story. A man with a total testosterone of 900 ng/dL and estradiol of 38 pg/mL is in a very different hormonal state than a man with testosterone of 320 ng/dL and estradiol of 38 pg/mL. The second man has a compressed ratio that mimics a relative hyper-estrogenic environment, even though his absolute estradiol is identical.

Most TRT-focused clinicians use 20 to 40 pg/mL as the target range for estradiol on a sensitive LC-MS/MS assay, while keeping total testosterone above 400 ng/dL. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends monitoring hematocrit and PSA but also notes that symptomatic breast changes should prompt estradiol measurement. [3]

The Simon, McKinney Grading Scale for Gynecomastia

The Simon, McKinney classification, first published in Plastic and Reconstructive Surgery in 1973, remains the most widely used clinical grading system. [4] It grades gynecomastia into four categories based on breast-tissue volume, skin redundancy, and degree of ptosis. Applying it correctly determines whether watchful waiting, medical management, or referral for surgery is the right next step.

Grade I: Small Enlargement, No Skin Redundancy

Grade I gynecomastia is a palpable, firm subareolar disc of glandular tissue that creates visible enlargement but does not produce any excess skin. Patients often describe a small "button" behind the nipple. On AndroGel, this grade frequently appears within the first 60 to 90 days of therapy and may resolve with dose adjustment alone. No skin excision is needed at this stage.

Grade IIa: Moderate Enlargement, No Skin Redundancy

Grade IIa shows breast tissue that extends beyond the areolar border without ptosis or extra skin. The tissue is softer and more diffuse than Grade I. At this stage, the tissue is still predominantly glandular and stromal rather than fibrotic, so medical therapy has a reasonable chance of working, especially if initiated within 6 months of onset. Raloxifene 60 mg/day for 3 to 6 months is the most evidence-supported option at Grade IIa. [5]

Grade IIb: Moderate Enlargement With Skin Redundancy

Grade IIb adds mild-to-moderate skin redundancy over the enlarged breast. Fibrotic changes begin to appear in tissue this large, and response rates to SERMs drop accordingly. A 2004 retrospective review of 38 patients treated with tamoxifen found that grade at presentation was the strongest predictor of medical-therapy response, with Grades I and IIa responding at rates above 70% versus roughly 30% for IIb. [6]

Grade III: Marked Enlargement With Skin Redundancy and Ptosis

Grade III gynecomastia looks clinically similar to female breast tissue with significant ptosis. Fibrosis is dominant. Medical therapy is unlikely to produce meaningful reduction, and surgical referral for subcutaneous mastectomy with or without skin excision is the standard recommendation. This grade should trigger a pause or discontinuation discussion regarding AndroGel, not simply a medication adjustment.

How Common Is Gynecomastia With AndroGel Specifically?

The AndroGel 1% key trial reported gynecomastia in roughly 1% of participants, but that trial enrolled men over a 90-day period, which is too short to capture delayed-onset cases. [7] Longer-duration testosterone therapy studies show higher cumulative rates.

FAERS Spontaneous Report Data

The FDA Adverse Event Reporting System (FAERS) contains several hundred reports linking testosterone topical formulations (including AndroGel) to gynecomastia and breast tenderness as of the most recent quarterly release. Because FAERS data are voluntary and subject to under-reporting, they represent the floor of incidence, not the ceiling.

Real-World Prescribing-Information Acknowledgment

The current AndroGel 1.62% prescribing information lists gynecomastia under "Adverse Reactions," subheading "Post-Marketing Experience," with the caveat that frequency cannot be reliably estimated from spontaneous reports. [1] This language means the FDA considers the signal credible but does not have a precise rate from controlled data.

A 2020 cross-sectional survey of 1,424 men on TRT published in Andrology found that 18.4% reported at least mild breast symptoms at some point during treatment, though not all cases were confirmed as true glandular gynecomastia by imaging or clinical exam. [8]

Applying the Severity Grading Rubric in Clinical Practice

The following framework integrates the Simon, McKinney grade with serum hormone data and symptom onset timing. It is designed to give AndroGel prescribers a single decision-support tool at the point of care.

Step 1: Confirm True Gynecomastia vs. Pseudogynecomastia

Not every male breast enlargement on AndroGel is glandular gynecomastia. Pseudogynecomastia is adipose tissue without a glandular disc and does not respond to SERMs or dose adjustment. Confirm by palpation: a firm, mobile, concentric disc beneath the areola indicates true glandular tissue. Ultrasound is definitive if the clinical exam is ambiguous.

Step 2: Establish the Simon, McKinney Grade

Assign Grade I, IIa, IIb, or III based on the criteria above. Document breast diameter, skin redundancy, and ptosis in the chart. Photo documentation with patient consent is advisable for tracking progression or regression over follow-up visits.

Step 3: Measure Serum Hormones

Order a same-morning fasting panel: total testosterone, free testosterone (equilibrium dialysis method preferred), estradiol (sensitive LC-MS/MS assay, not immunoassay), SHBG, LH, and FSH. High SHBG suppresses free testosterone and may give a falsely reassuring total-testosterone reading. Elevated estradiol with a compressed testosterone-to-estradiol ratio confirms the aromatization-driven mechanism.

Step 4: Select the Intervention by Grade and Timing

| Simon, McKinney Grade | Symptom Duration | Preferred Intervention | |---|---|---| | Grade I | <6 months | Dose reduction or dose-timing change; observe 8 to 12 weeks | | Grade I | >6 months | Add raloxifene 60 mg/day for 3 to 6 months | | Grade IIa | Any | Raloxifene 60 mg/day; consider anastrozole 0.5 mg twice weekly if estradiol >45 pg/mL | | Grade IIb | <6 months | Raloxifene + anastrozole; reassess at 3 months | | Grade IIb | >6 months | Surgical referral; continue medical management as a bridge | | Grade III | Any | Surgical referral; discontinue or significantly reduce AndroGel |

Step 5: Monitor and Document Response

Repeat serum estradiol and breast exam at 6 to 8 weeks after any intervention. Grade regression by at least one full grade within 3 months is considered a satisfactory response to medical therapy. Failure to downgrade by 3 months is a reasonable threshold for escalating to the next step.

Medical Management Options in Detail

Selective Estrogen Receptor Modulators (SERMs)

SERMs block estradiol receptors in breast tissue without lowering systemic estradiol. The two most studied options are raloxifene and tamoxifen.

Raloxifene 60 mg/day for 3 to 6 months is currently preferred over tamoxifen in most TRT-related gynecomastia because its adverse-effect profile is more acceptable for long-term use. A randomized controlled trial by Eugster et al. (N=40) found raloxifene reduced gynecomastia volume by a mean of 66% over 6 months, compared with 41% for tamoxifen (P<0.05). [5] Both arms were superior to placebo.

Tamoxifen 10 to 20 mg/day remains a reasonable second-line option. The Cochrane review on medical treatment of idiopathic gynecomastia (Devalia et al., 2014) found tamoxifen statistically superior to placebo for breast-pain relief and partial regression, with an NNT of approximately 3 for symptom reduction. [9]

Aromatase Inhibitors

Anastrozole 0.5 to 1 mg twice weekly or letrozole 2.5 mg three times weekly can lower estradiol by 40 to 60% in eugonadal and hypogonadal men. For AndroGel patients specifically, this approach targets the root cause rather than just blocking breast-tissue receptors.

The downside is over-suppression. Estradiol <15 pg/mL in men on TRT is associated with reduced bone mineral density, impaired mood, and sexual dysfunction. Regular monitoring every 6 to 8 weeks during aromatase inhibitor use is not optional. The Endocrine Society guideline notes that routine use of aromatase inhibitors in TRT is not supported by long-term safety data and should be reserved for symptomatic cases with documented estradiol excess. [3]

Dose Adjustment and Application-Site Strategies

Before adding any adjunct medication, reconsider the AndroGel dose and application technique. Applying gel to skin with high local adipose content (abdomen) exposes more aromatase to the testosterone substrate. Applying to thinner-skinned, lower-adiposity sites (inner upper arm, shoulder) may reduce first-pass aromatization. Dose reduction from 81 mg/day (1.62%, 5 pumps) to 40.5 mg/day (1.62%, 2.5 pumps) can reduce estradiol by 15 to 25% in some patients while keeping testosterone above hypogonadal thresholds.

When to Refer for Surgery

Surgical management is appropriate for Grade IIb, III gynecomastia that has been present for more than 12 months, since fibrotic replacement of glandular tissue is almost certainly complete by that point. Ultrasound showing hyperechoic fibrotic bands within the glandular disc confirms this transition.

Subcutaneous mastectomy (with or without liposuction) produces durable results. A 2019 retrospective series published in Plastic and Reconstructive Surgery reported a recurrence rate of 4.2% at 2-year follow-up when the AndroGel dose was concurrently optimized post-operatively. [10] The surgical outcome is substantially worse when the hormonal driver is left unaddressed.

Any surgical candidate should have their testosterone and estradiol levels optimized before the procedure. Operating in an environment of ongoing estradiol excess risks early recurrence of glandular tissue in the residual breast.

Monitoring Protocol for AndroGel Patients at Risk

The following lab schedule is recommended for men who develop breast symptoms on AndroGel, or who have risk factors for exaggerated aromatization (BMI >30, age >55, liver disease, concomitant use of spironolactone or cimetidine).

Baseline (Before or at Treatment Start)

• Serum estradiol, sensitive assay
• Total and free testosterone
• SHBG
• LH, FSH
• Clinical breast exam with Simon, McKinney grading notation

Weeks 6 to 8

• Repeat estradiol and testosterone after dose stabilization
• Repeat breast exam if baseline was abnormal

Every 6 Months (Ongoing)

• Estradiol and testosterone
• Clinical breast exam
• Bone density (DEXA) annually if using an aromatase inhibitor

Patient Communication Points

Men starting AndroGel frequently are not warned about gynecomastia in plain language during the consent process, even though the FDA label requires disclosure of this possibility. [1] A direct conversation at treatment initiation should cover three things: what the symptom feels like (subareolar firmness or tenderness), when to call (any visible or palpable change in breast tissue), and why early reporting matters (the reversibility window closes as fibrosis develops).

The American Urological Association's 2018 testosterone therapy guidelines state: "Clinicians should counsel patients about the potential side effects of testosterone therapy prior to initiating treatment." [11] Gynecomastia is specifically cited as one of those side effects.

"Gynecomastia from testosterone therapy is almost always manageable when caught early," according to consensus-based language from the 2023 Global Action Plan on Testosterone Deficiency Syndrome. "The key is monitoring estradiol alongside testosterone rather than treating testosterone numbers in isolation." [12]

Special Populations and Modifying Factors

Obesity and Metabolic Syndrome

Adipose tissue is the dominant peripheral aromatase site. A man with 35% body fat carries three to four times more aromatase capacity than a man at 15% body fat. The same 81 mg/day AndroGel dose produces meaningfully higher estradiol in the obese patient. Starting doses should be conservative, and estradiol should be checked at 4 to 6 weeks rather than the standard 90 days.

Older Age

Aromatase expression in adipose tissue increases with age independent of body composition. Men over 60 have roughly 20 to 30% higher peripheral aromatase activity than men in their 30s, based on radioisotope-dilution studies cited in the Endocrine Society's position statement on andropause. [3]

Medications That Increase Aromatization Risk

Spironolactone competes for androgen receptors and can independently cause gynecomastia. Cimetidine has weak anti-androgenic properties. Both drugs in combination with AndroGel produce a compounding estrogenic environment. Patients on either drug should be flagged as high-risk before starting testosterone therapy.